Kestra Medical general counsel Traci Umberger sells $900,882 of stock

Traci Umberger, General Counsel and Chief Administrative Officer at Kestra Medical Technologies, sold 30,000 shares of the company's stock for $900,882 on October 27, 2026. The sale was part of a pre-arranged trading plan established on July 21, 2026. The shares were sold at an average price of $30.0294 each. This sale occurred as KMTS stock was near its 52-week high of $31.04 following a 57% increase over six months.

Simultaneously, Umberger exercised options for another 30,000 shares at $17 per share, totaling $510,000, under the same trading plan. After these transactions, Umberger directly owns 195,825 shares of Kestra Medical Technologies and holds 411,000 options, with 365,919 fully vested and the remaining vesting monthly until March 6, 2027.

Umberger also serves as a Director for the company. Kestra Medical Technologies reported a 60% quarter-over-quarter revenue increase to $31 million in the first fiscal quarter of 2027, surpassing analyst expectations of $29 million. This revenue growth led to an upward revision of the company's full-year revenue guidance to $141 million.

Despite the revenue growth, Kestra reported a wider-than-anticipated loss of $0.75 per share, up from the expected $0.45 loss. Investment firms have shown varying opinions on Kestra's stock, with Evercore ISI rating it as an "outperform," Piper Sandler maintaining an "Overweight," and Stifel keeping a "Buy."